Phase 3 Clinical Trials With Primary Completion Dates in January 2026
This is a list of Phase 3 trials with primary completion dates in January 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | 2026-01-01 | Phase 3 | NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| BCTX | BriaCell Therapeutics Corp. | 2026-01-01 | Phase 3 | NCT06072612 | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
| CASBF | CanSino Biologics Inc. | 2026-01-01 | Phase 3 | NCT06857370 | Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine |
| PVLA | Palvella Therapeutics, Inc. | 2026-01-01 | Phase 3 | NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations |
| TBPH | Theravance Biopharma, Inc. | 2026-01-01 | Phase 3 | NCT05696717 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy |